2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
MODAG: positive phase 1 results of potential new Parkinson’s drug
Supported by Cure Parkinson’s, German Biotech company MODAG have announced positive results from their phase 1 clinical trial of Anle138b for Parkinson’s.
An overview of drug development for Parkinson’s
A recently published research report conducted by Parkinson’s research advocates and Cure Parkinson’s presents an encouraging overview of pipeline agents being clinically tested for Parkinson’s.
Dr Richard Wyse co-edits prestigious Cochrane Report
Cure Parkinson’s is honoured that our Director of Research, Dr Richard Wyse is co-editor of a new Cochrane Report titled ‘GLP‐1 receptor agonists for Parkinson’s disease’.
Further evidence of neuroprotection of simvastatin in Parkinson’s
Foundation, researchers have concluded that the elevated risk of Parkinson’s disease in patients with type ll diabetes might be mitigated depending on the type of drugs prescribed to treat this type of diabetes.
The liraglutide trial for people with Parkinson’s
This clinical trial will test the efficacy and safety of the diabetes drug liraglutide (a GLP-1 agonist) in people with Parkinson’s. The trial is taking place at the Cedars-Sinai Medical Center, Los Angeles, U.S. and was selected by the International Linked Clinical Trials committee; and is co-funded…